Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy

Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy

The purpose of this study is to investigate the effect of semaglutide in women with Polycystic Ovarian Syndrome(PCOS ) and determine potential therapeutic benefits.

The study mainly focused for the following objectives:

To determine the effect of semaglutide on ovulation and menstrual regularity. To determine the effect of semaglutide on androgen levels, namely testosterone, sex hormone binding globulin, and changes in hirsutism.

To determine changes in weight, body mass index (BMI), and Glycated Hemoglobin( HbA1c) with semaglutide therapy.

Inclusion Criteria:

• Age 18-45
• Body mass index(BMI) > 30
• Diagnosis of PCOS
• Normal thyroid stimulating hormone, prolactin, follicle-stimulating hormone (FSH), estradiol, and normal progesterone

Exclusion Criteria:

• Medications excluded: any hormone-containing contraceptive - oral contraceptive pills, Progesterone-only pill, depo-provera, oral provera, progesterone-containing intrauterine contraceptive device
• Letrozole, clomiphene citrate, FSH therapy
• Androgen receptor blockers
• 5α reductase inhibitors
• Insulin
• Hysterectomy
• Endometrial ablation